Heptavax-B in pediatric dialysis patients: effect of systemic lupus erythematosus

Marva M. Moxey-Mims, Karen Preston, Barbara Fivush, Fredrick McCurdy

Research output: Contribution to journalArticle

Abstract

Twenty-three pediatric dialysis patients 16 hemodialysis (HD) and 17 peritoneal dialysis (PD)], with a mean age of 13.9 years, were vaccinated against hepatitis B virus and their seroconversion rates were analyzed. There was no significant difference in the mean duration of dialysis between the HD and PD groups, or between responders and nonresponders to the vaccine. In the HD group, there was a response rate of 83.3% while the PD patients had a response rate of 88.2%. The only patients failing to seroconvert after the three vaccine series all had systemic lupus erythematosus and were taking oral corticosteroids.

Original languageEnglish (US)
Pages (from-to)171-173
Number of pages3
JournalPediatric Nephrology
Volume4
Issue number2
DOIs
StatePublished - Mar 1 1990

Keywords

  • Corticosteroids
  • Hemodialysis
  • Hepatavax-B
  • Peritoneal dialysis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Fingerprint Dive into the research topics of 'Heptavax-B in pediatric dialysis patients: effect of systemic lupus erythematosus'. Together they form a unique fingerprint.

  • Cite this